GBT Announces Participation in Upcoming Investor Conferences
06 mai 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following...
GBT Reports First Quarter 2021 Financial Results
05 mai 2021 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe Advanced pipeline programs inclacumab and...
GBT and Sickle Cell Disease Association of America Kick Off “Lift Every Voice to Shine the Light on Sickle Cell” Spoken Word Contest in Honor of World Sickle Cell Day 2021
04 mai 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and HANOVER, Md., May 04, 2021 (GLOBE NEWSWIRE) -- In recognition of World Sickle Cell Day, which falls on June 19, 2021, Global Blood Therapeutics, Inc. (GBT) (NASDAQ:...
GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021
28 avr. 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on...
Vollständige Ergebnisse nach 72 Wochen der Phase-3-HOPE-Studie zu Oxbryta® (Voxelotor) Tabletten in The Lancet Haematology veröffentlicht – signifikante Verbesserung von Hämoglobin, Hämolyse und der allgemeinen Gesundheit bei Patienten mit Sichelzellkrankheit
09 avr. 2021 07h27 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Kalifornien, April 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat heute bekanntgegeben, dass The Lancet Haematology die vollständige Analyse...
Les résultats complets à 72 semaines de l'étude HOPE de phase 3 sur Oxbryta® (voxelotor) en comprimés, publiés dans The Lancet Haematology, montrent une amélioration significative de l'hémoglobine, de l'hémolyse et de l'état de santé global chez les patients atteints de drépanocytose
09 avr. 2021 07h27 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Californie, 09 avr. 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que The Lancet Haematology a publié l'analyse...
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
08 avr. 2021 03h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of...
GBT Announces New Employment Inducement Grants
05 avr. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2021, the compensation committee of GBT’s board...
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
18 mars 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a...
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
16 mars 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively...